A new prostate cancer imaging technology from Clarity Pharmaceuticals (ASX:CU6) is showing promise in improving the detection of recurrent disease, after results from a comparative clinical study indicated it may outperform the current standard of care. …
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5. Ep.29
August 21, 2026 - - Podcast -
IDT Australia targets profitability after reporting sharply narrowing loss
August 21, 2026 - - Latest News -
Opportunity #5 - From the hardest thing to secure to the easiest thing to get right
August 21, 2026 - - Latest News -
Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation
August 21, 2026 - - Latest News -
Advent moves to acquire majority stake in NZCR Group
August 21, 2026 - -
Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma
August 21, 2026 - - Latest News -
New Zealand researchers honoured for work tackling superbugs and blood cancer
August 20, 2026 - - Latest News